1. Lawsuit-ridden J&J tumbles in annual listing of best global brands — AstraZeneca gets Q2 2020 PDUFA date for breast cancer ADC — Shionogi's antibiotic clears FDA panel vote — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Dova Pharmaceuticals

Discussion in 'Biotech Startups' started by anonymous, Mar 9, 2018 at 10:56 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Lol. Good luck with your “highly differentiated” me too.
     
  2. anonymous

    anonymous Guest

    I heard a lot of talk at the launch meeting about the company being sold soon. Anyone heard anything from higher level on this?
     
  3. anonymous

    anonymous Guest

    fingers crossed...lets hope it gets sold.
     
  4. anonymous

    anonymous Guest

    only a sucker would buy the dog that is Dova
     
  5. anonymous

    anonymous Guest

    Not true. D will be a 500M product in ITP The curve on this will be strong
     
  6. anonymous

    anonymous Guest

    You can’t really believe that?
     
  7. anonymous

    anonymous Guest

    okay. Fair enough. Let’s go with $300 MM. what are expectations for 1st year launch ?
     
  8. anonymous

    anonymous Guest

    does Dova still exist ?
     
  9. anonymous

    anonymous Guest

    What an absolute clown show
     
  10. anonymous

    anonymous Guest

    Is JM in Boston still fudging calls??
     
  11. anonymous

    anonymous Guest

    LOL
     
  12. anonymous

    anonymous Guest

    Does anyone know if those TBM's resigned or were forced out?
     
  13. anonymous

    anonymous Guest

    forced out-corrupt assholes
     
  14. anonymous

    anonymous Guest

    speaking of those things, what happened to the “leader” BN??? Karma, BM. Karma. Maybe this will make you a better person ???
     
  15. anonymous

    anonymous Guest

    forced out (already!) and (by the sound of the conference call this week) many others will be gone soon (unless you happen to have a big medical center in your backyard with drs that have been warehousing ITP patients for this drug!)
     
  16. anonymous

    anonymous Guest

    If you think the pressure is high now just wait! I heard that by this time after the launch last year, they were forcing the sales force to call on offices twice per week!?, firing people with no warning, and senior managers including the CEO (before he was fired!!) were calling at all hours and threatening the TBMs with termination
     
  17. anonymous

    anonymous Guest


    Should just sell the co and let big pharma do it. End this disaster already
     
  18. anonymous

    anonymous Guest

    Twice per week?--WTF? That big pharma high-pressure BS does not work in rare disease and definitely won't work in oncology. If they start that crap now, I'm gone. Nobody likes a pushy drug rep!
     
  19. anonymous

    anonymous Guest

    Agreed. The real focus here should be on the future with CIT not a 3rd in class "me too" indication. If they push the Drs too hard like last year, it will do huge damage.
     
  20. anonymous

    anonymous Guest

    What I am seeing in the ITP market is no different than what I experience in the CLD market. Physicians are not seeing a need to change their current practice patterns. The ITP indication is not the panacea that everyone hoped it would be. I heard Novartis has been sniffing around.